Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Athenex stock | $2.77

Learn how to easily invest in Athenex stock.

Athenex Inc is a drug manufacturers-specialty & generic business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 593 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Athenex

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATNX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Athenex stock price (NASDAQ: ATNX)

Use our graph to track the performance of ATNX stocks over time.

Athenex shares at a glance

Information last updated 2021-10-16.
Latest market close$2.77
52-week range$2.67 - $15.00
50-day moving average $3.22
200-day moving average $3.99
Wall St. target price$7.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.56

Buy Athenex shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Athenex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Athenex price performance over time

Historical closes compared with the close of $2.77 from 2021-10-15

1 week (2021-10-07) -2.81%
1 month (2021-09-16) -22.19%
3 months (2021-07-16) -30.40%
6 months (2021-04-16) -30.23%
1 year (2020-10-16) -77.86%
2 years (2019-10-17) -74.35%
3 years (2018-10-17) 14.09
5 years (2016-10-13) N/A

Athenex financials

Revenue TTM $120.2 million
Gross profit TTM $49 million
Return on assets TTM -23.44%
Return on equity TTM -99.88%
Profit margin -121.12%
Book value $1.69
Market capitalisation $302.8 million

TTM: trailing 12 months

Shorting Athenex shares

There are currently 4.3 million Athenex shares held short by investors – that's known as Athenex's "short interest". This figure is 48.7% down from 8.3 million last month.

There are a few different ways that this level of interest in shorting Athenex shares can be evaluated.

Athenex's "short interest ratio" (SIR)

Athenex's "short interest ratio" (SIR) is the quantity of Athenex shares currently shorted divided by the average quantity of Athenex shares traded daily (recently around 1.5 million). Athenex's SIR currently stands at 2.76. In other words for every 100,000 Athenex shares traded daily on the market, roughly 2760 shares are currently held short.

However Athenex's short interest can also be evaluated against the total number of Athenex shares, or, against the total number of tradable Athenex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athenex's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Athenex shares in existence, roughly 40 shares are currently held short) or 0.0627% of the tradable shares (for every 100,000 tradable Athenex shares, roughly 63 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Athenex.

Find out more about how you can short Athenex stock.

Athenex share dividends

We're not expecting Athenex to pay a dividend over the next 12 months.

Athenex share price volatility

Over the last 12 months, Athenex's shares have ranged in value from as little as $2.67 up to $15. A popular way to gauge a stock's volatility is its "beta".

ATNX.US volatility(beta: 0.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 0.6641. This would suggest that Athenex's shares are less volatile than average (for this exchange).

Athenex overview

Athenex, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product.

Frequently asked questions

What percentage of Athenex is owned by insiders or institutions?
Currently 13.426% of Athenex shares are held by insiders and 48.233% by institutions.
How many people work for Athenex?
Latest data suggests 593 work at Athenex.
When does the fiscal year end for Athenex?
Athenex's fiscal year ends in December.
Where is Athenex based?
Athenex's address is: Conventus Building, Buffalo, NY, United States, 14203
What is Athenex's ISIN number?
Athenex's international securities identification number is: US04685N1037
What is Athenex's CUSIP number?
Athenex's Committee on Uniform Securities Identification Procedures number is: 04685N103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site